SOHO 2022

2-Year Nonrecurrence Linked With Improved Long-Term Survival With Haplo-SCT

Researchers sought to determine whether there could be a link between haplo-SCT and survival in patients with hematologic malignancies who remain disease free for 2 years.

Camidanlumab Tesirine Appears Safe, Effective in Relapsed/Refractory Classical Hodgkin Lymphoma

Researchers sought to determine whether camidanlumab tesirine would be effective in patients with relapsed/refractory classical Hodgkin lymphoma.

Orca-T Improves Outcomes After Myeloablative Conditioning for Hematologic Malignancies

Researchers sought to determine whether Orca-T would improve outcomes for GVHD- and relapse-free survival after myeloablative conditioning.

Disparities in Multiple Myeloma Diagnosis and Outcomes Identified in Hispanic Patients

Researchers sought to determine whether there were disparities in diagnosis and outcomes in Hispanic patients with multiple myeloma.

Safety Profile of Isatuximab Confirmed in Real-World Study of Patients With Multiple Myeloma

Researchers sought to determine the real-world safety profile of isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory MM.

Patients With Diffuse Large B-Cell Lymphoma May Benefit From Shared Decision Making Schemes

Researchers sought to determine whether educational tools would help caregivers and physicians to better account for the lived experiences of some patients with DLBCL.

DOACs May Be a Viable Alternative to LMWH in Venous Thromboembolism

Researcher sought to determine whether DOACs would be an alternative to low molecular weight heparin in patients with lymphoma or plasma cell dyscrasia with VTE.

Though Improved, Outcomes Remain Poor for Patients With MDS Who Progress on HMA Therapy

Researchers sought to determine outcomes in patients with MDS whose disease progressed during treatment with hypomethylating agents.

Azacitidine May Improve Outcomes in a Subset of Patients With AML

Researchers sought to determine the safety and efficacy of oral azacitidine vs placebo among patients with AML.

Zanubrutinib Appears Superior to Ibrutinib in Patients With Relapsed/Refractory CLL/SLL

Researchers sought to determine whether zanubrutinib would have superior clinical outcomes to ibrutinib in patients with CLL/SLL.

Asciminib Improves MMR, Toxicity Compared With Bosutinib in CML-CP

Researchers sought to determine whether asciminib would be superior to bosutinib in patients with chronic myeloid leukemia in chronic phase.

Improvement in Hemoglobin and LDH Is Rapid With Pegcetacoplan in PNH

Researchers sought to determine whether patients with PNH treated with pegcetacoplan would have improvements in LHD and hemoglobin levels.

Midostaurin Maintenance Improved Survival in FLT3-Mutated Acute Myeloid Leukemia

Researchers sought to determine the efficacy of midostaurin maintenance therapy in patients with FLT3-mutated acute myeloid leukemia.

Detection of FLT3-ITD MRD Is Associated With Relapse and Death in AML

Researchers sought to determine whether detection of FLT3 internal tandem duplications would be prognostic of risk of relapse and death in AML.

Varying Efficacy Seen in Sequencing of Venetoclax and Targeted Therapies for Acute Myeloid Leukemia

Researchers sought to determine efficacy patterns with different approaches to sequencing of targeted treatments for patients with acute myeloid leukemia.

Chemotherapy-Free Regimen Shows Promise in Ph+ Acute Lymphoblastic Leukemia

Researchers sought to determine whether ponatinib plus blinatumomab would be effective for patients with Ph+ ALL.